Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.
The U.S. Food and Drug Administration approved the marketing of Benlysta in March as an add-on for lupus patients who are being treated with standard therapy.
The European and Canadian approvals have the same restriction.
Lupus is an autoimmune disease that attacks the body’s joints and internal organs.